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Abstract The European Paediatric Mycology Network
(EPMyN) was launched in 2014 to create a European platform
for research and education in the field of paediatric mycology.
The EPMyN aims to address the lack of paediatric specific
evidence and knowledge needed to (1) improve the manage-
ment and outcome of invasive fungal infections in children
and neonates and to (2) enhance and develop paediatric anti-
fungal stewardship programmes.
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Introduction
The European Paediatric Mycology Network (EPMyN) was
launched in 2014 to create a European platform for research
and education in the field of paediatric mycology. Its mission
is to increase the knowledge of the epidemiology and patho-
genesis and to improve the management of invasive fungal
infections in neonates and children. The detailed objectives
of the EPMyN are threefold: (1) to investigate the clinical
epidemiology of invasive fungal infections in neonates and
children, (2) to investigate new diagnostic and treatment mo-
dalities of fungal infections in specific paediatric groups, and
(3) to create a forum for educating and training colleagues in
the field of paediatric mycology.
The EPMyN is a member of PENTA-ID (www.penta-id.
org), a recognised level 1 network for paediatric infectious
diseases in Europe by the European Networks of Paediatric
Research at the European Medicines Agency (Enpr-EMA).
PENTA-ID was developed from the well-established PENTA
(Paediatric European Network for Treatment of AIDS) net-
work, originally collaboration between paediatric HIV centres
in Europe addressing relevant questions in the field of paedi-
atric HIV. Numerous clinical trials of antiretroviral therapies
in children have been successfully performed over more than
20 years and form the basis of current paediatric HIV treat-
ment guidelines [1]. PENTA-ID originates from the need to
integrate the expertise and experience gained by PENTA into
future studies in other paediatric infectious diseases. The po-
sitioning of EPMyN within PENTA-ID will benefit from ad-
ministrative and legal support, regulatory expertise and exten-
sive expertise in executing multicentre projects and clinical
trials. The EPMyN steering group brings together well-
known and recognised experts in various aspects of paediatric
mycology (neonatologists, paediatric haemato-oncologists,
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paediatric infectious diseases and immunology specialists,
clinical pharmacologists, pharmacist) and embraces a strong
combined experience in developing and performing paediatric
clinical trials.
Why
The need for EPMyNcan be found in the unique epidemiology
of invasive fungal infections in neonates and children, differ-
ences in pharmacokinetics of antifungal agents and usefulness
of fungal diagnostic measures compared to adults, and the
lack of clinical phase-III trials to assess the efficacy of anti-
fungal agents in the paediatric populations. The lack of pae-
diatric specific evidence results in inappropriate use of diag-
nostic measurements and antifungals and hampers the devel-
opment of paediatric antifungal stewardship programmes. Ar-
guments favouring the EPMyN, in addition to the well-
established International Paediatric Fungal Network (IPFN)
led by colleagues in the USA (www.ipfn.org), are the
differences in management strategies (e.g. influence of
antifungal prophylaxis, use of diagnostic measures),
differences in the fungal epidemiology and in the risk factors
associated with the development of invasive fungal infections
(e.g. antibiotic prescription policies). A number of colleagues
being a member of the EPMyN steering group are actively
involved in the IPFN as well and this does reflect the
complementarity of these two networks. In addition,
developing and executing cross-Atlantic clinical research, tak-
ing into account the differences in regulatory, data safety and
legal issues between the USA and Europe will enhance future
collaborative activities aimed at a better understanding and
improved outcome of invasive fungal infections in neonates
and children.
Education and Training
The EPMyN successfully organised its first post-graduate
course in Paediatric Mycology on October 12–13, 2015 in
Lisbon, Portugal. This post-graduate course was being held
in association with the Trends in Medical Mycology 2015, a
2-yearly conference jointly organised by the European Con-
federationMedical Mycology (ECMM) and the European Or-
ganisation for Research and Treatment of Cancer (EORTC).
During this 2-day course, the participants were provided with
state of the art lectures on the epidemiology, prevention, diag-
nosis and treatment of invasive fungal infections in neonates,
children with primary immunodeficiencies, children with ma-
lignancies and those undergoing haematopoietic stem cell
transplantation. Interactive case presentations with active in-
volvement of the participants led to vivid discussions and
revealed the absence of paediatric specific data to guide clin-
ical decisions.
Research
Current activities are focussed on collecting the necessary
information about the management of invasive fungal infec-
tions in children and neonates from a large number of Euro-
pean centres. This information is collected by an electronic
survey and the data is captured in the REDCap database.
The results of this survey are expected to define specific areas
of future research, to highlight gaps in paediatric specific
knowledge in clinical mycology and will emphasise difficul-
ties encountered in our daily practice which need to be ad-
dressed. In addition, specific surveys are being developed to
obtain an enhanced insight in the epidemiology of invasive
mould infections in the paediatric population, to describe the
experience of fluconazole dosing in neonates with a focus on
the use of higher dosages as suggested by recent pharmacoki-
netic studies [2–4] and to assess the incidence of azole-
resistant Aspergillus fumigatus in the paediatric population.
Next to these investigator-initiated studies, EPMyN aims to
provide a platform for pharmaceutical companies to assist in
developing and performing the studies as required in the so-
called paediatric investigation plan (PIP) set out by the Euro-
pean Medicines Agency (www.ema.europa.eu). Investigating
new antifungals in paediatrics do require specific expertise
compared to clinical trials in adults. A PIP need to consider
an appropriate medicine’s formulation acceptable for use in
children, the need of coverage of all paediatric age groups
from birth to adolescence and how to measure its efficacy
and side effects. The EPMyN within the PENTA-ID is able
to cover those paediatric specific aspects and will provide in
expertise needed.
Guidelines and Antifungal Stewardship
Only recently, professional organisations have noticed that the
development of paediatric specific guidelines for the manage-
ment of invasive fungal infections has been an unmet need
and have undertaken a valuable effort to realise the develop-
ment of paediatric specific guidelines. The European Society
Clinical Microbiology and Infectious Diseases (ESCMID)–
Fungal Infections Study Group (EFISG) guideline for the
management of invasive candidiasis in neonates and children
was the first to be published [5•]. In this guideline, both pro-
phylaxis and treatment of invasive candidiasis in both neo-
nates and children are well-addressed. Currently, the guideline
for the management of invasive aspergillosis in neonates, chil-
dren with primary immunodeficiencies and children with can-
cer is in preparation and its publication is expected in 2016.
The executive summary has been presented at the European
Conference Clinical Microbiology and Infectious Diseases
(ECCMID) in 2014. This guideline will cover recommenda-
tions with respect to diagnostic measurements as well as pro-
phylaxis and treatment of invasive aspergillosis. Next to these
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two fungal disease-oriented guidelines, a guideline for the
management of invasive fungal infections in paediatric pa-
tients with leukaemia and haematopoietic stem cell transplan-
tation has been published [6•]. This guideline has been devel-
oped within the European Conference on Infections in Leu-
kaemia (ECIL) addressing a specific patient population. Al-
though the development of guidelines is not seen as a task per
se of the EPMyN, various members of the steering group are
and have been actively involved in the preparation of those
guidelines.
In complementation of these guidelines, the development
of an outline of a paediatric antifungal stewardship pro-
gramme to be used as a format in individual European coun-
tries is under consideration. The need for a paediatric antifun-
gal stewardship programme is directly related to the chal-
lenges encountered in the management of invasive fungal in-
fections in neonates and children, the development of antifun-
gal resistance and the high costs of inappropriate antifungal
prescriptions. Invasive fungal infections are characterised by
unspecific signs and symptoms in already extremely vulnera-
ble children (e.g. premature neonates, children with primary
immunodeficiencies or malignancies, and those receiving
haematopoietic stem cell or solid organ (e.g. liver, lung) trans-
plants), poor-sensitivity of culture-based microbiologic tests,
and the pressure to start treatment early due to the high mor-
bidity and mortality of these infections. Most antifungals in
paediatric settings are therefore prescribed for empiric/pre-
emptive therapy. Suboptimal dosing of antifungals in neonates
and children has been described and may contribute to subop-
timal clinical outcomes [7•, 8]. To successfully develop and
implement a paediatric AFS programme, evaluation and iden-
tification of current gaps in resources and knowledge among
healthcare workers involved in the diagnosis and treatment of
invasive fungal infections in neonates and children is a key
step. This information is currently being collected by us.
Conclusion
Collaborative efforts in the field of paediatric mycology are
critical to improve our knowledge and to facilitate research
with the ultimate goal of improving the management and out-
come of invasive fungal infections in children and neonates.
The EPMyN has taken up the responsibility to provide a plat-
form for research and education in the field of paediatric my-
cology. The activities undertaken by the EPMyNwill facilitate
the development of paediatric specific antifungal stewardship
programmes built on increased evidence and knowledge.
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